C. Robinson

发表

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania

S. Kapiga, D. Watson-Jones, P. Kaleebu, 2019, The Journal of infectious diseases.

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

H. Schuitemaker, Yvonne Wollmann, R. Roozendaal, 2020, NPJ vaccines.

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

S. Lees, D. Watson-Jones, B. Lowe, 2021, The Lancet. Infectious diseases.

Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen

H. Tinto, I. Valéa, R. Thiébaut, 2023, medRxiv.

Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children

D. Watson-Jones, Pauline Akoo, D. Ishola, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

M. McElrath, O. Anzala, D. Heerwegh, 2021, PLoS medicine.

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

V. Bockstal, Benoît Callendret, Auguste Gaddah, 2020, The Journal of infectious diseases.

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

M. McElrath, S. D. De Rosa, M. Pau, 2022, PloS one.

Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.

D. Watson-Jones, C. McLean, G. Deen, 2022, The Lancet. Infectious diseases.

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

M. McElrath, O. Anzala, D. Heerwegh, 2022, PLoS medicine.

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

S. Lees, D. Watson-Jones, B. Lowe, 2021, The Lancet. Infectious diseases.

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.

Y. Lévy, A. Pollard, J. Lelièvre, 2020, The Lancet. Infectious diseases.

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

O. Anzala, V. Bockstal, M. Douoguih, 2019, The Journal of infectious diseases.

Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign

E. Karita, S. Allen, S. Nsanzimana, 2022, The Journal of infectious diseases.

Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory

D. Watson-Jones, O. Anzala, S. Sirima, 2023, EBioMedicine.

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

H. Schuitemaker, D. Heerwegh, R. Roozendaal, 2022, npj Vaccines.

Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone

D. Watson-Jones, D. Ishola, E. Smout, 2022, Emerging infectious diseases.

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

H. Schuitemaker, Yvonne Wollmann, R. Roozendaal, 2023, Frontiers in immunology.

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

O. Anzala, V. Bockstal, M. Douoguih, 2019, The Journal of infectious diseases.

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

V. Bockstal, Auguste Gaddah, M. Douoguih, 2021, NPJ vaccines.

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial

E. Karita, S. Allen, S. Nsanzimana, 2022, Trials.

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

V. Bockstal, Auguste Gaddah, M. Douoguih, 2021, npj Vaccines.

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

H. Schuitemaker, Yvonne Wollmann, R. Roozendaal, 2020, npj Vaccines.

Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda

D. Watson-Jones, P. Kaleebu, Zacchaeus Anywaine, 2020, Global health action.

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

S. Lees, D. Watson-Jones, M. Belson, 2020, Trials.

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen

D. Watson-Jones, C. Drakeley, S. Soremekun, 2023, Vaccines.